- In May 2023, Sysmex Corporation (Japan), a leader in hematology diagnostics, announced the launch of an enhanced flow cytometry-based AML testing platform aimed at improving the precision and speed of leukemia diagnosis. The new platform integrates automated analysis with advanced software algorithms, enabling clinicians to differentiate AML subtypes more accurately. This development emphasizes Sysmex’s commitment to advancing hematological diagnostics and improving clinical outcomes for AML patients globally
- In April 2023, F. Hoffmann-La Roche Ltd (Switzerland) expanded access to its next-generation sequencing (NGS) solutions for leukemia diagnosis through its NAVIFY® Mutation Profiler, designed to assist oncologists in interpreting genetic data. By streamlining complex genomic insights, this tool enhances personalized treatment planning for AML patients. This launch reinforces Roche’s strategic focus on precision oncology and the increasing role of genomics in AML diagnostics
- In March 2023, Bio-Rad Laboratories, Inc. (U.S.) unveiled its updated QX600 Droplet Digital PCR (ddPCR) system, optimized for detecting low-frequency mutations associated with AML. The technology enables sensitive detection of minimal residual disease (MRD), aiding clinicians in monitoring disease progression and therapeutic response. This advancement showcases Bio-Rad’s emphasis on enabling early and accurate disease monitoring using advanced molecular diagnostics
- In February 2023, Illumina, Inc. (U.S.) partnered with regional oncology centers in Asia to implement comprehensive NGS-based panels for leukemia, including AML. The collaboration aims to expand access to high-quality diagnostic solutions in emerging markets by providing customized genomic testing protocols and clinical interpretation support. This effort illustrates Illumina’s global expansion strategy and its dedication to democratizing access to high-precision cancer diagnostics
- In January 2023, Agilent Technologies Inc. (U.S.) launched a new myeloid panel within its SureSelect portfolio, designed specifically for the detection of clinically relevant mutations in AML. The panel integrates seamlessly with NGS workflows and is intended to support research and diagnostics in clinical laboratories. This innovation reflects Agilent’s growing investment in oncology and the rising demand for targeted, gene-based AML testing solutions
